DE69218948T2 - IGF-I zur Verbesserung der neuronale Lage - Google Patents

IGF-I zur Verbesserung der neuronale Lage

Info

Publication number
DE69218948T2
DE69218948T2 DE69218948T DE69218948T DE69218948T2 DE 69218948 T2 DE69218948 T2 DE 69218948T2 DE 69218948 T DE69218948 T DE 69218948T DE 69218948 T DE69218948 T DE 69218948T DE 69218948 T2 DE69218948 T2 DE 69218948T2
Authority
DE
Germany
Prior art keywords
nervous system
central nervous
analogues
insulin
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69218948T
Other languages
English (en)
Other versions
DE69218948D1 (de
Inventor
Peter Gluckman
Karoly Nikolics
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Genentech Inc
Original Assignee
Auckland Uniservices Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19923685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69218948(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auckland Uniservices Ltd, Genentech Inc filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of DE69218948D1 publication Critical patent/DE69218948D1/de
Publication of DE69218948T2 publication Critical patent/DE69218948T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE69218948T 1991-08-01 1992-08-03 IGF-I zur Verbesserung der neuronale Lage Revoked DE69218948T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ23921191 1991-08-01
PCT/US1992/006389 WO1993002695A1 (en) 1991-08-01 1992-08-03 Igf-1 to improve the neural condition

Publications (2)

Publication Number Publication Date
DE69218948D1 DE69218948D1 (de) 1997-05-15
DE69218948T2 true DE69218948T2 (de) 1997-07-31

Family

ID=19923685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69218948T Revoked DE69218948T2 (de) 1991-08-01 1992-08-03 IGF-I zur Verbesserung der neuronale Lage

Country Status (9)

Country Link
US (2) US5714460A (de)
EP (1) EP0597033B1 (de)
AT (1) ATE151293T1 (de)
CA (1) CA2114251C (de)
DE (1) DE69218948T2 (de)
DK (1) DK0597033T3 (de)
ES (1) ES2101865T3 (de)
GR (1) GR3023874T3 (de)
WO (1) WO1993002695A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) * 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
CA2136969C (en) * 1992-06-12 2009-03-24 Michael E. Lewis Prevention and treatment of peripheral neuropathy
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
SE9301667D0 (sv) * 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
WO1995013823A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
WO1995017204A1 (en) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
US5656605A (en) * 1994-01-26 1997-08-12 Institute Of Molecular Biology, Inc. Device to promote drug-induced nerve regeneration
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5965531A (en) * 1995-08-31 1999-10-12 National Institutes Of Health Method of reducing perivascular lesions using insulin-like growth factor I
WO1997021449A1 (en) * 1995-12-13 1997-06-19 Aurogen Incorporated Method for effecting changes in the central nervous system by administration of igf-i or igf-ii
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
WO1999020299A1 (en) * 1997-10-17 1999-04-29 Spencer E Martin Human urinary incontinence and methods of treatment
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
EP1087782A4 (de) * 1998-06-15 2001-09-12 Neuronz Ltd Regulation der tyrosinhydroxylase
ES2329220T3 (es) 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
EP1141014B1 (de) 1999-01-06 2004-12-08 Genentech, Inc. Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
WO2001037855A2 (en) * 1999-10-27 2001-05-31 Chiron Corporation Temperature dependent neuronal rescue
EP1282437B1 (de) 2000-05-16 2008-03-19 Genentech, Inc. Behandlung von knorpelerkrankungen
ES2346185T3 (es) * 2000-08-29 2010-10-13 Aurogen Incorporated Metodo para tratar el sistema nervioso central mediante la administracion de analogos estructurales de igf.
US20030027755A1 (en) * 2000-12-08 2003-02-06 Jian Guan Compositions and methods for the rescue of white matter
AU2002255508B2 (en) * 2001-02-09 2008-04-03 Genentech, Inc. Crystallization of IGF-1
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7041314B2 (en) 2001-05-24 2006-05-09 Neuren Pharmaceuticals Ltd. GPE analogs and peptidominetics
US6861406B2 (en) 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
GB0202906D0 (en) * 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
NZ545940A (en) 2003-09-12 2009-12-24 Tercica Inc Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
US7192738B2 (en) * 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
US7220729B2 (en) * 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment
EP1674113A1 (de) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
EP2012815A4 (de) * 2006-04-14 2009-12-09 Massachusetts Inst Technology Identifikation und modulierung molekularer pfade zur vermittlung neuronaler plastizität
KR101106795B1 (ko) 2006-08-31 2012-01-18 에프. 호프만-라 로슈 아게 인슐린-유사 성장 인자-ｉ의 제조 방법
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
CA2720478A1 (en) * 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Pegylated insulin-like-growth-factor assay
MX2010010495A (es) * 2008-04-03 2010-10-15 Hoffmann La Roche Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
EP3299023A4 (de) * 2015-05-21 2019-03-20 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Sauerstoffarm behandelte mesenchymale stammzelle und deren verwendung
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
AU2019271189A1 (en) 2018-05-15 2021-01-07 Lloyd Hung Loi TRAN Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5817623A (en) 1995-03-06 1998-10-06 Univ Colorado State Res Found Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
WO1991002067A1 (en) * 1989-07-27 1991-02-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Regulation of nerve growth factor synthesis in the central nervous system
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US20070078089A1 (en) 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II

Also Published As

Publication number Publication date
GR3023874T3 (en) 1997-09-30
CA2114251A1 (en) 1993-02-18
EP0597033A1 (de) 1994-05-18
ATE151293T1 (de) 1997-04-15
EP0597033B1 (de) 1997-04-09
CA2114251C (en) 2007-11-06
DE69218948D1 (de) 1997-05-15
ES2101865T3 (es) 1997-07-16
US5714460A (en) 1998-02-03
WO1993002695A1 (en) 1993-02-18
USRE43982E1 (en) 2013-02-05
DK0597033T3 (da) 1997-06-02

Similar Documents

Publication Publication Date Title
DE69218948D1 (de) IGF-I zur Verbesserung der neuronale Lage
HK1048058A1 (zh) 肝臟選擇性的藥用活性物
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EP0476044A4 (en) Treating disorders by application of insulin-like growth factors and analogs
EP0682526A4 (de) VERABREICHUNG VON sCR1 UNDANDEREN KOMPLEMENTINHIBITOREN ÜBER DIE LANGE.
HK1003978A1 (en) Composition for the treatment of schizophrenia
CA2122058A1 (en) Tgf-beta to improve neural outcome
HU913447D0 (en) Medical preparations and their use in treating neurologic disorders
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
NO990088D0 (no) Farmas÷ytiske preparater omfattende S-(-)-N-propargyl-1-aminoindamin
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
ZA911496B (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
MY131805A (en) Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
EP0515434A4 (en) Method for treating intestinal diseases
EP0744176A3 (de) Arzneimittel zur Hemmung von Knochenschwund
DE69307702T2 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
HK1003422A1 (en) A method of treating liver disease and like indications with vasodilating agents
MD1296G2 (ro) Metoda Nicolau de tratament al lichenului plan bucal
NZ330758A (en) Treatment of neural damage using GPE (the tripeptide gly-pro-glu)
EP0147194A3 (en) Method and compositions for treating cerebral ischemia

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation